The FDA outlines new regulatory actions to accelerate development of psychedelic therapies for serious mental illnesses following an HHS directive.
Written By: Pharmacally Medical News Desk
Following an April 18 executive directive from Donald Trump, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration have initiated regulatory measures to accelerate the development of treatments for serious mental illnesses, including complex and treatment-resistant conditions.
As part of this effort, the FDA is advancing regulatory pathways for serotonin 2A receptor agonists, a class of perception-altering psychedelic compounds being studied for therapeutic use in psychiatric disorders.
The agency has issued national priority vouchers to support three investigational programs focused on psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder (PTSD).
These measures are intended to streamline development timelines, particularly for therapies that may demonstrate early clinical benefit.
HHS Secretary Robert F. Kennedy Jr. stated that the initiative is designed to accelerate research and enable responsible access to emerging mental health treatments, including psychedelic-based therapies, especially for populations such as veterans and patients with limited treatment options.
FDA Commissioner Marty Makary noted that while these investigational therapies may offer potential in addressing conditions such as treatment-resistant depression, substance use disorders, and PTSD, their development must remain grounded in rigorous scientific evaluation and supported by robust clinical evidence to establish safety and effectiveness.
In a related action, the FDA has cleared an Investigational New Drug application allowing a Phase I clinical trial of noribogaine hydrochloride to proceed in the United States.
Noribogaine is a derivative of ibogaine, a psychoactive compound sourced from the African plant Tabernanthe iboga, and is being studied as a potential treatment for alcohol use disorder, a condition associated with high relapse rates and limited therapeutic options.
The study, sponsored by DemeRx NB, represents the first FDA-authorized clinical investigation of an ibogaine-derived compound in the U.S. The agency emphasized that this authorization permits the study to begin under controlled conditions but does not indicate that the drug has been approved or proven safe or effective.
The FDA also indicated that it will soon release final guidance for sponsors developing serotonin 2A agonists and related therapies, outlining key considerations for clinical trial design, patient monitoring, and data generation.
Tracy Beth Hoeg said the agency recognizes increasing interest in the potential of psychedelic compounds for difficult-to-treat psychiatric conditions and is supporting their evaluation through structured and scientifically rigorous clinical research.
In a separate development, Compass Pathways expressed support for regulatory efforts aimed at accelerating research and access to psychedelic-based treatments. The company, which is developing psilocybin therapy for treatment-resistant depression, indicated that initiatives which streamline clinical development and provide clearer regulatory pathways could help in advancing evidence-based psychiatric therapies while maintaining appropriate safety and scientific standards.
Reference
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order | HHS.gov
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order | FDA
